Provencio, M, Nadal, E, Insa, A, Campelo, MRG, Calvo, V, Palmero, R, Lázaro, M, Dómine, M, Majem, M, Rodríguez-Abreu, D, Martínez-Martí, A, Carpeño, JDC, Cobo, M, Bernabé, R, Viñolas, N, Barneto, I, Viteri, S, Cruz-Bermudez, A, Romero, A, Massutí, B. Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial). Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Garcia-Campelo, R, Gómez, MD, de Castro, J, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Dols, MC. Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Martínez-Toledo, C, Sierra, B, Molina-Alejandre, M, Casarrubios, M, Calvo, V, Nadal, E, Campelo, MRG, Martínez-Martí, A, Garrido, A, Massutí, B, Insa, A, De Castro, J, Dóomine, M, González-Larriba, JL, Majem, M, Ponce, S, Barneto, I, Aguilar, A, Martín-López, J, Provencio, M, Cruz-Bermúdez, A. TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Spigel, DR, Ahn, MJ, Majem, M, Rodríguez, LM, Lee, KH, Carcereny, E, Hernández, AA, Insa, A, Cho, EK, Besse, B, Rha, SY, Weiss, J, D'Arcangelo, M, Im, SA, Kim, SW, Carneiro, BA, Gadgeel, SM, Mitchell, P, Asare, JM, Gainer, SD, Achour, I, Subramaniam, DS, Felip, E. Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Nguyen, D, Besse, B, Cho, BC, Lee, SH, Lee, KH, Lu, S, Cheng, Y, Yao, Y, Girard, N, Lin, CC, Felip, E, Aguilar, A, Charoentum, C, Cruz, FJSM, Majem, M, Lim, CS, Akamatsu, H, Hayashi, H, Yang, JCH, Kowalyszyn, R, Tiscoski, K, Franke, F, Ponomarenko, D, Arslan, C, Forster, M, Urban, D, Misch, D, Delmonte, A, Montes, LVG, Gadgeel, SM, Cruz-Correa, M, Peguero, J, Rousey, S, Gaffar, Y, Owen, S, Schuchard, J, Diels, J, Sermon, J, Sun, T, Ennis, M, Fennema, E, Daksh, M, Sethi, S, Bauml, JM, Campelo, MRG. Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).

Cardozo, A, Lleida, R, Szafranska, J, Piñol, D, Serdà, P, Martin-Cullell, B, Manrique, A, López-Bravo, D, Mateo, FJ. From the Rare to the Extraordinary Pancreatic Serous Cystadenocarcinoma With Hepatic and Bone Dissemination: A Letter to the Editor. PANCREAS. 2024; 53(9)DOI:10.1097/MPA.0000000000002362. PMID:39250559. IF:1.700(Q3/8D).

Sullivan, I, Aguado, C, Baroni, M, Teixeira, S, Bertran, J, Giménez, A, Aldeguer, E, Román, R, Reguart, N, López, L, Cavagna, R, Marín, E, García, B, Rodriguez, S, Rosell, R, Ferro, L, Chae, Y, Reis, R, Molina, MA. RET overexpression in absence of fusions or mutations associates with sensitivity to RET TKIs in lung cancer. EUROPEAN JOURNAL OF CANCER. 2024; 211DOI:10.1016/j.ejca.2024.114800. PMID:. IF:7.100(Q1/2D).

Esquirol, A, Pascual, MJ, Montoro, J, Piñana, JL, Ferrà, C, Herruzo, B, Garcia-Cadenas, I, Balaguer, A, Perez, A, Huguet, M, Redondo, S, Villalba, M, Hernandez-Boluda, JC, Chorao, P, Hernani, R, Sanz, J, Solano, C, Sierra, J, Martino, R. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil. Transplantation And Cellular Therapy. 2024; 30(10)DOI:10.1016/j.jtct.2024.07.027. PMID:39116938. IF:4.400(Q1/1D).

Spyridonidis, A, Labopin, M, Savani, B, Kulagin, A, Blaise, D, Versluis, J, Sica, S, Raiola, AM, Vydra, J, Choi, G, Rovira, M, Kwon, M, Sanz, J, It la-Remes, M, Borne, PV, Martino, R, Koc, Y, Brissot, E, Nagler, A, Mohty, M, Ciceri, F. THE IMPACT OF INDIVIDUAL COMORBIDITIES ON NRM RISK FOLLOWING PTCY BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN ALWP EBMT STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Serrano, JD, Corral, LL, Valc rcel, D, Sierra, J, Ferra-Coll, C, Velazquez, TC, Dom nguez, FM, Le n, RJ, Ortega, JLR, Go i, CB, L pez, EP, Mart nez, AC, Cadenas, IG, Sim n, JAP. DELAYED ADMINISTRATION OF IXAZOMIB AS PROPHYLAXIS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Gagelmann, N, De Witte, M, Peczynski, C, Boreland, W, Broers, A, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Byrne, J, Bethge, W, Maertens, J, St lzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kr ger, N, Corradini, P, Finazzi, MC, Corral, L, Villar, S, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

G mez, VE, Corral, LL, Mahillo, BA, Mellado, PA, Dom nguez, FMM, G mez, MA, Cant , PA, G mez, JM, Ochando, MT, Borrego, AB, Pinedo, LG, Ripa, MTZ, Vicent, MG, Vallejos, AB, Izquierdo, I, Cadenas, IG, Velao, SR, Musseti, A, Giro, EC, Moraleda, PP, Pascual, GO, Sierra, PAG, Garc a, L, Guti rrez, VG, P rez-Sim n, JA. RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Salas, MQ, Solano, MT, Baile-Gonz lez, M, Acera-G mez, M, Fox, L, del Mar P rez-Artigas, M, Santamar a, A, Quintela-Gonz lez, MDC, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Gonz lez, SR, Mussetti, A, Lavilla, E, L pez-Marin, J, Cedillo, A, Bento, L, Sureda, A. FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Fern ndez-Barge, T, Dom nguez-Garcia, JJ, Escamilla, MS, Caballer, JS, Chorao, P, Boluda, JCH, Velao, SR, Cadenas, IG, Bufarull, RM, Estefania, RC, Alexandre, IF, Pe a, AG, Garc a, AT, Ruiz, RG, Luis, SF, San Miguel, EMO, Ara jo, MC, Pell n, SGD, Rodr guez, MAB. OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Salas, MQ, Solano, MT, Baile-Gonzalez, M, Acera-G mez, M, Fox, L, Perez-Artigas, MD, Santamar a, A, Quintela-Gonz lez, MD, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Rodr guez-Gonz lez, S, Mussetti, A, Abuin-Blanco, A, Lopez-Mar n, J, Filarerro, S, Bento, L, Sureda, A. FRAILTY SYNDROME IN ADULTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-CT). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).

Abras, A, Ballart, C, Fernández-Arévalo, A, Llovet, T, Gállego, M, Muñoz, C. Assessment of Alinity s Chagas® as a Primary Diagnostic Test for Chronic Chagas Disease in a Non-Endemic Area of Europe (Barcelona, Spain). Life-Basel. 2024; 14(10)DOI:10.3390/life14101278. PMID:39459578. IF:3.400(Q1/3D).

Feliu-Soler, A, Royuela-Colomer, E, Navarrete, J, Jorgensen, NN, Mariño, M, Demarzo, M, Soler, J, García-Campayo, J, Montero-Marín, J, Luciano, JV. Assessing the Impact of the Way of Saint James on Psychological Distress and Subjective Well-being: The Ultreya Study. Journal of Happiness Studies. 2024; 25(7)DOI:10.1007/s10902-024-00820-0. PMID:. IF:3.300(Q1/1D).

Fortea, J. Context matters: the evolving use of biomarkers in Alzheimer's disease care. EBioMedicine. 2024; 108DOI:10.1016/j.ebiom.2024.105387. PMID:39366842. IF:10.800(Q1/1D).

Koetsier, J, Cavill, R, Reijnders, R, Harvey, J, Homann, J, Kouhsar, M, Deckers, K, Kohler, S, Eijssen, LMT, van den Hove, DLA, Demuth, I, Düzel, S, Smith, RG, Smith, AR, Burrage, J, Walker, EM, Shireby, G, Hannon, E, Dempster, E, Frayling, T, Mill, J, Dobricic, V, Johannsen, P, Wittig, M, Franke, A, Vandenberghe, R, Schaeverbeke, J, Freund-Levi, Y, Frölich, L, Scheltens, P, Teunissen, CE, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Engelborghs, S, de Roeck, E, Martinez-Lage, P, Tainta, M, Lleó, A, Sala, I, Popp, J, Peyratout, G, Verhey, F, Tsolaki, M, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Vos, SJB, Lovestone, S, Visser, PJ, Lill, CM, Bertram, L, Lunnon, K, Pishva, E. Blood-based multivariate methylation risk score for cognitive impairment and dementia. ALZHEIMERS & DEMENTIA. 2024; 20(10)DOI:10.1002/alz.14061. PMID:39193899. IF:11.100(Q1/1D).

Smith, RG, Pishva, E, Kouhsar, M, Imm, J, Dobricic, V, Johannsen, P, Wittig, M, Franke, A, Vandenberghe, R, Schaeverbeke, J, Freund-Levi, Y, Frölich, L, Scheltens, P, Teunissen, CE, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Engelborghs, S, de Roeck, E, Martinez-Lage, P, Altuna, M, Tainta, M, Lleó, A, Sala, I, Popp, J, Peyratout, G, Winchester, L, Nevado-Holgado, A, Verhey, F, Tsolaki, M, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Vos, SJB, Lovestone, S, Visser, PJ, Bertram, L, Lunnon, K. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study. ALZHEIMERS & DEMENTIA. 2024; 20(10)DOI:10.1002/alz.14098. PMID:39193893. IF:11.100(Q1/1D).